Region Hovedstadens Psykiatriske
- Address
- lock Available on a paid plan
Biomarkers in Clozapine‑Responding Schizophrenia
Researchers at the Mental Health Center Glostrup are investigating biological biomarkers that may predict how patients with schizophrenia respond to clozapine treatment, aiming to move toward more personalized care.
- Identification of predictive biomarkers for clozapine efficacy
- Correlation of biomarker profiles with clinical outcomes
- Development of tools for individualized treatment decisions
This work supports the site’s broader focus on improving outcomes for individuals living with severe mental disorders.
Long‑Term Safety of Iclepertin in Schizophrenia
A follow‑up study is collecting extended safety data on patients with cognitive impairment due to schizophrenia who previously received Iclepertin, to ensure the therapy remains well‑tolerated over time.
- Monitoring adverse events beyond the initial treatment phase
- Assessing impact on cognitive function and daily living
- Comparing long‑term safety with placebo outcomes
The investigation reflects the center’s commitment to safe, effective interventions for cognitive deficits in mental illness.
Acute Effects of Partial GABA(A)-Receptor Modulation (TOTEMS)
The TOTEMS trial examines how the investigational compound GT‑002, a partial GABA(A)-receptor modulator, influences brain activity and cognitive impairment in patients across the schizophrenia spectrum.
- Measurement of event‑related EEG and EMG responses
- Evaluation of hypofrontality as a mechanistic marker
- Short‑term effects on attention, memory, and processing speed
Findings may guide new strategies to address the persistent cognitive challenges faced by many individuals with psychotic disorders.
Add‑On Memantine Trial for First Episode Psychosis (AMEND)
In the AMEND study, researchers are testing whether adding memantine to standard antipsychotic therapy can lessen negative symptoms in patients experiencing a first episode psychosis.
- Reduction of anhedonia, avolition, and social withdrawal
- Exploration of glutamate system modulation alongside dopamine blockade
- Assessment of functional recovery and quality of life
This approach seeks to improve early treatment outcomes for young adults confronting psychotic illness.
KarXT for Acute Mania in Bipolar‑I Disorder
A phase‑3 investigation evaluates the efficacy of KarXT combined with mood stabilizers (lithium, valproate, or lamotrigine) in reducing the severity of acute mania, with or without mixed features, in bipolar‑I disorder patients.
- Comparison of mania severity scores between KarXT and placebo groups
- Monitoring of safety and tolerability alongside standard mood stabilizers
- Exploration of rapid symptom relief and functional improvement
Success could expand therapeutic options for individuals struggling with severe mood episodes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Region Hovedstadens Psykiatriske2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Region Hovedstadens Psykiatriske3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Hovedstadens Psykiatriske
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Trospium Chloride | 2 | Unknown | 2025-09-25 | 2026-03-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.